Chise Profile picture
Feb 8, 2021 14 tweets 3 min read Read on X
Let’s talk about immunity and why it’s important to take certain factors into consideration when we look at these studies and maybe why the most recent one on AstraZeneca’s effectiveness on the B.1.351 is a tad bit bothersome. For starters this beauty wasn’t tweeted initially.
See that last bullet point? The one of T-cell immunity. Yeah, that’s vital. Why? The study failed to discuss this aspect. You cannot disregard T-cells in the same breath you are discussing B-cells, vaccines and their respective induced antibody responses. It’s a package deal.
T-cells help protect against severe disease. Their analysis shows 76 out of 87 TCB sites (87%) are NOT impacted by the mutations seen in B.1.351. What does this mean? It means the T-cell response generated by AstraZeneca’s vaccine should be highly effective against this variant.
How are you going to disregard our actual immune systems and their ability to make antibodies for later?
Which may I remind you are DRIVEN by vaccines. They teach our bodies to make antibodies for later, not just during active infection (memory T-cells anyone). That’s immunity!
T-cells stimulate B-cells to make antibodies. Antibodies are just your first line of defense which is what is initiated when you get this vaccine. It’s our T-cells that are responsible for long-term immunity. When antibodies diminish after your initial inoculation, your T-cells-
will tell your B-cells it’s time to produce more antibodies. As long as your T-cells still recognize this virus and inform your B-cells they need to produce antibodies, the vaccine is still doing its job. Antibodies being built up over and over again is nothing new or unique-
to this vaccine, this is how vaccines have always worked. This study does not account for this information concerning T-cell immunity at all and then leaves this last bit til the end of the presentation (go figure). Just a heads up, your TCRs and your BCRs target different parts
of the Coronavirus’ spike protein.
Antibodies can prevent infection, your T cell-responses ensure that those antibodies keep doing their job and they kick in after you're infected OR oh my goodness stop the presses- VACCINATED (how about them apples).
In other words, while robust T-cells responses cannot protect you from a mild or moderate infection sometimes (think cough, sniffles, etc.) they can however proliferate rapidly and prevent the build up of viral load. Psst- you want this to be LOW. VL drives disease severity.
So why am I bothered? Because we have half-baked self-proclaimed (excuse my rudeness) experts stating this vaccine is now 10% effective and instilling panic. I’m here to tell you that is FALSE. So, yes, you and your loved ones who received this vaccine? You’re still protected!
Realize this last comment was towards no one specific. I had heard that numerous media outlets were claiming the “10%.” I wasn’t even sure who had presented initially. I was told this was a leaked screen by FT that had to be presented after the fact. My explanation still stands.
So from what I am being told this morning, South Africa is resuming administering doses of AstraZeneca and lifted their halt, but continuing to study its efficacy closely.
Let me reiterate once more, my comments are towards no one specific, including the original presenter. I said “experts” as in plural. This was a broad statement as several media outlets & “experts” were reporting the “10%” efficacy misinformation. My science still stands.
I wanted to add/adjust my statement earlier concerning South Africa resuming rollout of AstraZeneca’s vaccines. They are administering 100,000 doses and then monitoring in a “stepped manner.” Remember, based on what I discussed above, you are still protected if you received it.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Chise

Chise Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

Oct 28, 2024
THIS IS HUGE! An HIV PrEP drug candidate in the form of a twice-yearly subcutaneous injection has been shown to reduce HIV infections by 96% in a SECOND late-stage Phase III trial. Lenacapavir was 99.9% effective at preventing HIV in MORE THAN 2,000 participants.🧵⬇️
These results come from the PURPOSE 2 trial evaluating Gilead Sciences’ twice-yearly, subcutaneous Lenacapavir in individuals aged 16 years or older. Lenacapavir, which is a capsid inhibitor, is already approved by the FDA under the brand name Sunlenca for use alongside other
Read 13 tweets
Oct 24, 2024
So, not COVID related BUT, this is REALLY exciting news. Phase I/II data shows Moderna’s Norovirus vaccine candidate mRNA-1403, has shown early signs of efficacy AND elicited robust serum HBGA-blocking antibody responses against ALL THREE NoV genotypes. Let’s talk about that!🧵⬇️
At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II, randomized, observer-blind, placebo-controlled, dose-ranging trial (NCT05992935) for mRNA-1403, a prophylactic vaccine candidate under investigation for norovirus (NoV) infections.
As one of the leading causes of acute gastroenteritis worldwide, NoV is associated with a substantial healthcare burden. Symptoms include vomiting and diarrhoea, which can be severely dehydrating, and the risk of severe outcomes from NoV is greatest in young children and older
Read 16 tweets
Oct 21, 2024
THIS IS HUGE! Researchers at JHU have developed an experimental drug called RK-33, that in preclinical studies has shown promise in treating breast cancer with bone metastases. RK-33 eliminated the metastases AND prevented further cancer spread. Let’s talk about that!🧵⬇️
The research has been published in Cancer Letters. Yes, it is PEER-REVIEWED.
sciencedirect.com/science/articl…Key Takeaways:  •RK-33 targets DDX3, an RNA helicase elevated in cancer cells, to inhibit breast cancer bone metastasis.  •In mouse models, RK-33 eliminated bone metastases and prevented further cancer spread without significant adverse effects.  •The study suggests RK-33 as a promising treatment for breast cancer bone metastasis, urging further research into its broader applications.
In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously shown to help treat other types of cancer and viral illnesses.
Read 14 tweets
Oct 17, 2024
THIS IS HUGE! Researchers at Lancaster University have developed RI-AG03, a peptide inhibitor, that in preclinical studies PREVENTED the build-up of harmful Tau proteins in the brain, which are believed to be a key driver of Alzheimer’s disease. Let’s talk about that! 🧵⬇️
The research has been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Yes, it is PEER-REVIEWED.
•~ alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…What You Need to Know ⬇️  •Scientists have developed a new drug that targets two key regions of the tau protein, a major contributor to Alzheimer’s disease.  •The drug, a peptide inhibitor called RI-AG03, successfully prevented the build-up of toxic tau proteins in both laboratory and fruit fly studies.  •Although further research is necessary, including clinical trials in humans, this research contributes to the advancement of more effective therapies for neurodegenerative diseases.  •There are two main “hotspots” on the tau protein, where fibril clumping occurs. In this new study, research...
Tau proteins are essential for maintaining the structure and function of neurons. However, in Alzheimer’s disease, these proteins malfunction and aggregate into long, twisted fibrils. As these fibrils build up, they form neurofibrillary tangles- masses of tangled tau proteins
Read 15 tweets
Oct 9, 2024
THIS IS HUGE! Researchers at the University of Pennsylvania have developed a vaccine against the bacterium Clostridioides difficile (C.diff), that in preclinical studies, protected against succumbing from infection AND prevented recurring cases. Let’s talk about that! 🧵⬇️
The study has been published in Science. Yes, it is PEER-REVIEWED.
science.org/doi/10.1126/sc…Model figure. (A) C. difficile toxins target the intestinal epithelium and cause severe pathology and gastrointestinal disease leading to morbidity and mortality. (B) When vaccinated mice are infected with C. difficile, anti-toxin IgG and IgA protect mice from disease and inclusion of PPEP-1 and CdeM as immunogens improves decolonization of toxigenic C. difficile from the gastrointestinal tract. Credit: Science (2024). DOI: 10.1126/science.adn4955
The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals-
Read 15 tweets
Oct 5, 2024
THIS IS HUGE! Scientists at the University of Oxford are developing the world's FIRST ovarian cancer vaccine that could potentially wipe the disease out. OvarianVax teaches the immune system to recognize and attack the earliest stages of ovarian cancer. Let’s talk about that!🧵⬇️
The hope is that individuals could receive the vaccine preventatively with the goal of eradicating the disease. Researchers have suggested it could work in a similar way to the human papillomavirus (HPV) vaccine, which is on track to stamp out cervical cancer.
Oxford researchers are designing OvarianVax, a vaccine which teaches the immune system to recognize and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(